20/20 Biolabs, Inc. Common Stock (AIDX)vsNovartis AG ADR (NVS)
AIDX
20/20 Biolabs, Inc. Common Stock
$1.49
-1.97%
HEALTHCARE · Cap: $15.62M
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2766415% more annual revenue ($56.58B vs $2.05M). NVS leads profitability with a 23.9% profit margin vs -182.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
AIDX
Avoid15
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -503.0% — below average capital efficiency
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
AIDX has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : AIDX
The primary concerns for AIDX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
AIDX is growing revenue faster at 0.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 15/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (ticker: AIDX) is a forward-thinking biotechnology company dedicated to advancing genomic research and diagnostics through innovative laboratory services. By focusing on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is at the forefront of molecular diagnostics. With a strong commitment to harnessing cutting-edge technologies, 20/20 Biolabs is well-positioned to lead the charge in personalized medicine as the demand for genomic data accelerates. The company’s strategic initiatives and robust market positioning signal a promising growth trajectory in the dynamic biotechnology sector.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?